WEC
NVCR icon

Winslow Evans & Crocker’s NovoCure NVCR Stock Holding History

Winslow Evans & Crocker’s Portfolio NVCR Stock Details NVCR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		– Sell
-20
Closed -$2K – 1345
2020
Q3 		$2K Hold
20
– – ﹤0.01% 1015
2020
Q2 		$1K Hold
20
– – ﹤0.01% 1100
2020
Q1 		$2K Hold
20
– – ﹤0.01% 1037
2019
Q4 		$2K Hold
20
– – ﹤0.01% 1096
2019
Q3 		$2K Hold
20
– – ﹤0.01% 1087
2019
Q2 		$2K Hold
20
– – ﹤0.01% 1086
2019
Q1 		$2K Buy
+20
New +$963 ﹤0.01% 1210

Other funds holding NVCR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
CS
Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Winslow Evans & Crocker's NVCR Position: Q4 2020 in Review

Winslow Evans & Crocker sold out of NovoCure (NVCR) in Q4 2020, closing a stake of 20 shares — an estimated $2K sold.

Winslow Evans & Crocker first reported a position in NVCR in Q1 2019 and held it in 7 quarters. The position peaked at $2K in Q3 2020. 356 funds tracked by Wall St. Rank hold NVCR as of Q4 2020.

  • Winslow Evans & Crocker reported no remaining NovoCure position as of Q4 2020 after selling out during the quarter.
  • Winslow Evans & Crocker sold 20 NovoCure shares in Q4 2020, an estimated $2K.
  • Winslow Evans & Crocker first reported a position in NovoCure in Q1 2019 and held it in 7 quarters.
  • Winslow Evans & Crocker's NovoCure position peaked at $2K in Q3 2020.
  • 356 funds tracked by Wall St. Rank held NovoCure as of Q4 2020.

Based on Winslow Evans & Crocker's 13F filing for Q4 2020, filed 3 Feb 2021.